Heart Failure With Preserved Ejection Fraction Clinical Trial
Official title:
The Effect of a High Fiber Diet and High-Intensity Interval Exercise in Patients With Heart Failure With Preserved Ejection Fraction
NCT number | NCT05236413 |
Other study ID # | HSR210393 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2022 |
Est. completion date | August 1, 2025 |
This study is trying to find out how best to improve common measures of health and survival in those diagnosed with heart failure with preserved ejection fraction (HFpEF) through the implementation of 4 weeks of an exercise training program consisting of high intensity interval training, dietary approaches to stop hypertension (DASH diet), or a combination of the two. Currently there are not established guidelines that have been shown to improve clinical end points in those with this HFpEF.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | August 1, 2025 |
Est. primary completion date | August 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - =40 years of age - Diagnosed with heart failure with preserved ejection fraction - NYHA class II-III symptoms - Physician clearance to undergo exercise training - Physician clearance to consume DASH diet - Complete COVID-19 vaccination status Exclusion Criteria: - Unstable angina - Myocardial infarction in the past 4 weeks - Uncompensated heart failure - NYHA class IV symptoms - Complex ventricular arrhythmias - Musculoskeletal contraindications to stationary bicycling exercise - Symptomatic severe aortic stenosis - Acute pulmonary embolus - Acute myocarditis - Uncontrolled hypertension - Medication non-compliance - Unable to follow DASH diet - Food allergies (Nuts, wheat) - Pregnant women |
Country | Name | City | State |
---|---|---|---|
United States | University of Virginia University Hospital | Charlottesville | Virginia |
Lead Sponsor | Collaborator |
---|---|
University of Virginia | Grain Foods Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | NTproBNP | Assess changes in NTproBNP (pg/ml) as a biomarker of myocardial strain at pre- and post-intervention | 4 weeks | |
Other | Inflammation | C-reactive protein (mg/dl) will be used as a biomarker for inflammation to be measured pre- and post-intervention | 4 weeks | |
Other | Lipids | A lipid panel will be performed to measure total cholesterol, triglycerides, high-density lipoproteins, and low-density lipoprotein (mg/dl) to assess changes in cardiometabolic health pre- and post-intervention | 4 weeks | |
Other | Insulin | Fasting insulin levels (U/ml) will be tested to assess changes in cardiometabolic health pre- and post-intervention | 4 weeks | |
Other | Fasting Blood Glucose | Fasting blood glucose levels (mg/dl) will be tested to assess changes in cardiometabolic health pre- and post-intervention | 4 weeks | |
Other | Endothelin-1 | Arterial vasoconstrictor tone will be assessed by serum endothelin-1 (pg/mL) at pre- and post-intervention. | 4 weeks | |
Other | Lipopolysaccharide | Gut mucosal health and inflammation as measured by plasma Lipopolysaccharides (ng/mL) pre- and post-intervention | 4 weeks | |
Other | Trimethylamine-N-oxide | Trimethylamine-N-oxide (µM) will be used to assess gut mucosal health and inflammation pre- and post-intervention | 4 weeks | |
Primary | VO2peak | Change in VO2peak (L/min) measured pre- and post-intervention | 4 weeks | |
Secondary | Diastolic Function | E' and A' (cm/s) will be used to calculate the E'/A' ratio to assess for diastolic dysfunction and be measured by echocardiogram pre- and post-intervention | 4 weeks | |
Secondary | Ejection Fraction | Ejection fraction (%) will be used to assess changes in cardiac contractile function and be measured by echocardiogram pre- and post-intervention | 4 weeks | |
Secondary | Global Longitudinal Strain | Global longitudinal strain (%) will be used to assess changes in cardiac contractile function and be measured by echocardiogram pre- and post-intervention | 4 weeks | |
Secondary | Blood pressure | Changes in measures of central and brachial blood pressure (mmHg) at pre- and post-intervention | 4 weeks | |
Secondary | Carotid-Femoral Pulse Wave Velocity | Changes in arterial stiffness as measured by carotid-femoral pulse wave velocity (m/s) at pre- and post-intervention | 4 weeks | |
Secondary | Body Composition | Changes in lean and fat mass (grams) will be measured via dual-energy x-ray absorptiometry pre-and post-intervention | 4 weeks | |
Secondary | Physical Activity Enjoyment Scale | Subject enjoyment of exercise will be measured using the Physical Activity Enjoyment Scale. This is an 18 item questionnaire which assess how subjects feel about the exercise they have been performing. Questions are scored using a 7-point likert scale | Immediately after the intervention | |
Secondary | Minnesota Living with Heart Failure Questionnaire | Disease specific quality of life will be measured using the Minnesota Living with Heart Failure Questionnaire (MLHFQ). he MLHFQ consists of 21 items that assess physical and emotional domains. Each item/question is scored on a 0-5 Likert scale. | 4 weeks | |
Secondary | Epworth Sleepiness Questionnaire | The Epworth sleepiness questionnaire is an 8 item questionnaire that measures how likely someone would be to fall asleep in 8 different scenarios. Each item is graded on a 4 point likert scale ranging from "would never nod off" to "high chance of nodding off". | 4 weeks | |
Secondary | Pittsburgh Sleep Quality Index | Sleep quality and sleep disturbances over the pervious month will be measured with the Pittsburgh sleep quality index (PSQI). The PSQI include 19 item self directed questions which look at a measures of sleep quality and a disturbances. It also includes 5 questions to be answered by a roommate (if available) regarding the patients sleep habits. | 4 weeks | |
Secondary | Circadian Type Questionnaire | The Circadian Type Questionnaire is an 19 item VAS that is used to assess someones ability to change their sleeping habits. | 4 weeks | |
Secondary | Sleep Apnea | Changes in sleep apnea will be measured using a WatchPAT device. This device measured finger peripheral arterial tone and measures arterial volume changes in the finger. This reflect changes in sympathetic tone and is associated with sleep disordered breathing. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05839730 -
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
Recruiting |
NCT06379152 -
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT05676684 -
Dapagliflozin, Spironolactone or Both for HFpEF
|
Phase 2/Phase 3 | |
Recruiting |
NCT04153136 -
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
|
Phase 2 | |
Recruiting |
NCT06114498 -
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT05715697 -
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT04745013 -
PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart
|
N/A | |
Completed |
NCT05586828 -
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
|
||
Completed |
NCT05126836 -
Cilostazol for HFpEF
|
Phase 2 | |
Recruiting |
NCT04594499 -
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
|
||
Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
Completed |
NCT04535726 -
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
|
||
Recruiting |
NCT03550235 -
Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
|
||
Completed |
NCT04633460 -
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
|
Phase 2 | |
Completed |
NCT06228807 -
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
|
||
Active, not recruiting |
NCT05284617 -
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
|
Phase 2 | |
Recruiting |
NCT05562063 -
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
|
Phase 4 | |
Recruiting |
NCT06027307 -
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
|
Phase 3 | |
Withdrawn |
NCT05322616 -
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
|
Phase 1 |